Scaling Clinical Diagnostic Testing to the Masses (Part 2)

The rising cost of health care has hit Americans differently depending on their economic status. There is no shortage of news stories covering the reality of  those with higher incomes having higher life expectancies than those in lower financial brackets. Healthcare services such as clinical diagnostic testing may be out of reach for those who could really use it. So what are some the things a company can do to make clinical diagnostic testing more accessible for everyone? How can an important medical test be affordable to all?

On this episode of Health & Life Sciences at the Edge, host Michelle Dawn Mooney talks with Intel Head of Business Innovation and Life Science Specialist Blake Harlan and SiPhox Chief Product Officer Mike Dubrovsky about clinical diagnostic testing, the way it is used, and the way its use can be improved.

“Clinical diagnostic testing is actually a major part of the [healthcare] system,” says Dubrovsky. “Seventy percent of all medical decisions require diagnostic tests. However, the way that it’s done now is very reactive, so the whole system is based on first the patient having symptoms and then they’re put through a series of tests to try to resolve the problem.” Harlan and Dubrovsky further mention how it’s easy for those in higher income brackets to get tested more often, as those types of tests cost much more than the ones for reactive patients who are presently experiencing symptoms.

“The way the healthcare system works now is it’s really set up to, for the person, once they get sick, to deal with that” says Dubrovsky. He points out how the system is primarily designed to treat reactive care. “The problem is that there is a massive rise in healthcare costs, accompanied with actually a decrease in life expectancy, at least in America”, where six out of ten Americans have at least one chronic disease. In a country that spends so much on healthcare research, Harlan and Dubrovsky think the country needs to shift its thinking and policies when it comes to the health of its citizens.

Learn more about network operations center solutions by connecting with Blake Harlan and Mike Dubrovsky on LinkedIn or visiting SiPhox or Intel Health and Life Sciences.

Listen to Part One right here.

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More